

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TWI PHARMACEUTICALS INC.,

Petitioner,

v.

MERCK SERONO SA,

Patent Owner.

IPR2023-00049 (Patent 7,713,947 B2)

Before ULRIKE W. JENKS, ZHENYU YANG and TINA HULSE,
Administrative Patent Judges.

PETITIONER'S REPLY TO PATENT OWNER'S RESPONSE

TABLE OF CONTENTS

	Page
TABLE OF CONTENTS	i
TABLE OF AUTHORITIES.....	iii
I. The Challenged Claims Are Anticipated By The Bodor Art.	1
A. The Bodor Art Is “By Another.”	1
B. Bodor Discloses Weight-Based Dosing.....	6
1. <i>Differing Patient Weights Is The Only Reason For Differing Total Doses</i>	7
2. <i>Fixed, Flat Dosing</i>	8
3. <i>Patent Owner Incorporation by Reference</i>	9
C. A PHOSITA Would Read Bodor To Disclose A Maintenance Period.....	11
1. <i>Bodor’s Expressly Teaches That The Period Of No Treatment Ends After 10 Months</i>	11
2. <i>Alternatively, Resumption Of Treatment Is The Only Reasonable Inference A PHOSITA Would Draw From Bodor’s Disclosure</i>	12
II. The Challenged Claims Are Obvious Over Bodor In View Of The General Knowledge of a PHOSITA.	14
A. Any Element Bodor May Be Deemed Not To Disclose Within Its Four Corners Would Have Been Obvious To A PHOSITA Based On Their General Knowledge.....	14
B. A PHOSITA would have had a motivation and reasonable expectation of success to repeat Bodor’s regimen.....	15
III. The Challenged Claims Are Obvious Over Bodor In View Of Rice 2000.....	19
A. Bodor and Rice 2000 teach all limitations.	19

B. Motivation to Combine and Expectation of Success20

IV. No Secondary Considerations Overcome The Strong Showing Of
Obviousness.20

V. Conclusion23

CERTIFICATION OF WORD COUNT1

CERTIFICATE OF SERVICE2

TABLE OF AUTHORITIES

CASES

<i>Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc.</i> , 25 F.4th 1354 (Fed. Cir. 2022)	21
<i>Advanced Display Sys., Inc. v. Kent State Univ.</i> , 212 F.3d 1272 (Fed. Cir. 2000)	10
<i>Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc.</i> , 752 F.3d 967 (Fed. Cir. 2014)	22
<i>Cohesive Techs., Inc. v. Waters Corp.</i> , 543 F.3d 1351 (Fed. Cir. 2008)	21
<i>Dayco Prods., Inc. v. Total Containment, Inc.</i> , 329 F.3d 1358 (Fed. Cir. 2003)	10
<i>Duncan Parking Techs., Inc. v. IPS Grp., Inc.</i> , 914 F.3d 1347 (Fed. Cir. 2019)	2, 5
<i>Hockerson-Halberstadt, Inc. v. Avia Grp. Int'l, Inc.</i> , 222 F.3d 951 (Fed. Cir. 2000)	3
<i>ModernaTx, Inc. v. Arbutus Biopharma Corp.</i> , 18 F.4th 1352 (Fed. Cir. 2021)	8
<i>Riverwood Int'l Corp. v. R.A. Jones & Co.</i> , 324 F.3d 1346 (Fed. Cir. 2003)	3
<i>Spectra-Physics, Inc. v. Coherent, Inc.</i> , 827 F.2d 1524 (Fed. Cir. 1987)	7
<i>WBIP, LLC v. Kohler Co.</i> , 829 F.3d 1317 (Fed. Cir. 2016)	21

STATUTES

35 U.S.C. § 102	1, 2
-----------------------	------

REGULATIONS

37 C.F.R. § 1.57	3, 10
------------------------	-------

Petitioner TWi Pharmaceuticals Inc. (“Petitioner”) respectfully submits this Reply to Paper 28, Patent Owner’s Response (“*PO’s Resp.*”), and in further support of Paper 1, its Petition (“*Petition*”).

I. The Challenged Claims Are Anticipated By The Bodor Art.

Bodor discloses all elements of the challenged claims. (*See* Ex. 1047, Greenberg Rebuttal Decl. ¶ 15.)

A. The Bodor Art Is “By Another.”

Patent Owner’s assertion that the named inventors of the challenged patent also conceived the relevant disclosure in Bodor is legally insufficient, inconsistent with its position during prosecution and not born out by the evidence.

First, Patent Owner’s argument that Bodor is not prior art under 35 U.S.C. § 102(b) (*PO’s Resp.* 8 n.3) fails because the challenged claims are due a priority date no earlier than December 18, 2009. As explained in the Petition, the challenged claims (added by amendment dated December 18, 2009, Ex. 1003, 405–423) recite a regimen in which the maintenance period dose can be *equal* to the induction period dose. (*Petition* 10–11.) Every previous filing (including provisional Ser. No. 60/638,669 (Ex. 1003, 301–332 at 309), EP 04106909 (Ex. 1003, 268–299 at 276), PCT/WP2005/056954 (Ex. 1003, 333–364 at 340–41), Ser. No. 11/722,018 (*Id.*), and all earlier amendments) all required that the total dose in the maintenance period be *less than, not equal to* the total dose in the induction period. These claims in the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.